Abstract
The products of the BRCA breast cancer susceptibility genes have been implicated in cell cycle control and DNA repair. It has been suggested that mutations in the p53 gene are a necessary step in tumorigenesis in BRCA tumors. We tested samples from 402 breast cancer patients for germ-line BRCA2 and p53 mutations in tumors. p53 mutations are more frequent in BRCA2 mutation carriers than they are in controls. Tumors with mutations in either gene had multiple chromosomal abnormalities, as shown by cytogenetic analysis.
Footnotes
-
↵1 This work was supported by grants from The Icelandic Cancer Society Fund, Nordic Cancer Union, Icelandic Research Fund for Higher Education, University of Iceland Science Fund, and Icelandic Science Council.
-
↵2 To whom requests for reprints should be addressed, at Molecular and Cell Biology Research Laboratory, Icelandic Cancer Society, P.O. Box 5420, 125 Reykjavik, Iceland. E-mail: jorunn@krabb.is.
- Received November 4, 1997.
- Accepted January 19, 1998.
- ©1998 American Association for Cancer Research.
Volume 58, Issue 5
